Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
brevican Double Nickase Plasmid (h): sc-402668-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- brevican Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- brevican Double Nickase Plasmid (h) and brevican Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting BCAN. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: brevican Antibody (2): sc-135849
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
brevican Double Nickase Plasmid (h) | sc-402668-NIC | 20 µg | $410.00 | |||
brevican Double Nickase Plasmid (h2) | sc-402668-NIC-2 | 20 µg | $410.00 |
BCAN encodes brevican, a brain-enriched chondroitin sulfate proteoglycan that is a prominent component of the extracellular matrix and perineuronal nets. Brevican contributes to neural development and synaptic stabilization by modulating cell–matrix interactions, neurite outgrowth, and extracellular diffusion properties in the CNS. Through interactions with hyaluronan-binding partners and other matrix constituents, it influences extracellular matrix organization, neuronal plasticity, and tissue remodeling processes. Altered BCAN expression and brevican processing have been associated with neurodevelopmental and neurodegenerative phenotypes and have been investigated in the context of CNS injury and glioma-associated extracellular matrix remodeling.
brevican Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the BCAN locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within BCAN. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt BCAN function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of BCAN-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.